Kitov’s development and commercialization pipeline includes two oncology therapies and the company’s first FDA-approved product, Consensi™.
CM-24 – clinical-stage monoclonal antibody blocking CEACAM1, a novel immune checkpoint expressed in multiple tumor types that supports tumor evasion and survival through multiple pathways.
NT-219 – first-in-class, small molecule dual-inhibitor of two key cancer resistance pathways – STAT3 and IRS1/2.
Consensi™ – fixed-dose combination of celecoxib and amlodipine besylate for the simultaneous treatment of osteoarthritis pain and hypertension that was approved by the FDA for marketing in the US in 2018. Consensi is expected to be launched in H1 2020 by Kitov’s partner, Coeptis Pharmaceuticals.